Abstract: At present, chemotherapy for non-small cell lung cancer (NSCLC) has reached a therapeutic plateau; new treatment options are needed to improve efficacy. Bevacizumab is a vascular endothelial growth factor monoclonal antibody. It is the first targeted therapy confirmed to improve the chemotherapy survival in advanced NSCLC. Many clinical studies about bevacizumab as first-line, second-line, adjuvant, and neoadjuvant treatments with chemoradiation are ongoing. The article reviews the current indications for beva -cizumab.